Metro-Minnesota Community Clinical Oncology Program

描述（由申请人提供）： Metro-Minnesota Community Clinical Oncology Program（MMCCOP）代表由九家医院组成的联盟，通过其NCI资助的社区医院肿瘤学计划（“CHOP”）和运营CCOP，开发了一种管理癌症患者的通用方法，并建立了识别、输入和跟踪患者治疗和癌症预防和控制方案的机制。该联合体有一个全社区的计算机化数据管理系统，能够收集未来的数据。社区提供PPO、HMO和商业医疗保健计划，所有这些都在这九家联盟医院中有代表。这九家医院每年平均有9700名新的分析性癌症患者。代表医学和放射肿瘤学、血液学、泌尿学、妇科肿瘤学、神经学、耳鼻喉科、家庭诊所、普通和专业外科医生的100名核心和待定的新研究者在癌症项目开发和当前项目结构和操作的方案开发方面进行了广泛的合作。在最近一个由国家癌症研究所资助的资助年度（6/03-5/04），880名患者/参与者（192.3治疗学分+ 299.6癌症控制学分）被累积到国家癌症研究所批准的治疗和癌症预防和控制研究中。MMCCOP旨在维持一个区域范围的社区和医院联盟，为社区提供癌症预防，控制和治疗的最新进展。这将通过以下方式实现：进一步将CCOP扩大到已建立的外联社区;与医院、基金会、保险公司和综合服务网络合作，为参与临床试验提供资金和报销支助;增加初级保健医生的参与;提供发展所需的专业知识、资源和庞大的人口基础，通过与NCI、CTSU、ECOG、GOG、MD安德森、NSABP、RTOG、URCC的合作以及与NCCTG的试点项目，实施和评估临床癌症治疗和控制试验;改进和扩大目前的MMCCOP数据管理和通信系统，以增加调查人员参与权责发生制、方案业务和研究基地活动的数量和水平;实施新战略，改善少数族裔和服务不足群体的获取和参与;提高专业人士和非专业社区对CCOP和临床癌症试验益处的认识。根据过去的经验，癌症控制和预防试验的可用性，多个研究基地和成功的癌症控制实施模式，MMCCOP研究人员打算招募1040人（581.6学分/413.5新+ 168.1随访）患者/参与者在第一年内参加了NCI批准的癌症治疗和对照研究，目标是不断超过NCI对这两类研究的要求。先前的MMCCOP申请被当时的审查人员视为“过于乐观”，但被超越。该赠款第一年的目标仍然是乐观的，但考虑到该小组的专业知识、现有的协议、既定的系统以及医生和医院的大力支持，这是现实的。

DESCRIPTION (provided by applicant): The Metro-Minnesota Community Clinical Oncology Program (MMCCOP) represents a consortium of nine hospitals which, through its NCI-funded Community Hospital Oncology Program ("CHOP") and operational CCOP, has developed a common approach to the management of cancer patients and has an established mechanism for identifying, entering and following patients on treatment and cancer prevention and control protocols. The consortium has a community-wide computerized data management system capable of prospective data collection. The community offers PPO's, HMOs and commercial healthcare programs, all of which are represented among these nine consortium hospitals. Together, the nine hospitals see an average of 9700 new analytic cancer patients per year. The 100 core and pending new investigators, representing medical and radiation oncology, hematology, urology, gynecologic oncology, neurology, ENT, family practice, general and specialty surgeons, have worked extensively together on cancer program development and protocol development of the current program structure and operation. During the most recent NCI-funded grant year (6/03-5/04), 880 patients/participants (192.3 treatment credits+ 299.6 cancer control credits) were accrued to NCI-approved treatment and cancer prevention and control studies. The MMCCOP intends to sustain a region wide community and hospital consortium, which provides the community with the most recent advances in cancer prevention, control and treatment. This will be accomplished through further expansion of the CCOP into established outreach communities; work with hospitals, foundations, insurers and Integrated Service Networks (ISNs) to develop funding and reimbursement support for participation in clinical trials; increased involvement of primary care physicians; providing the expertise, resources, and large population base to develop, implement and evaluate clinical cancer treatment and control trials through affiliation with the NCI, CTSU, ECOG, GOG, MD Anderson, NSABP, RTOG, URCC and pilot project with the NCCTG; improve and expand the current MMCCOP data management and communication system to increase the number and level of participation of the investigators in accrual, program operations and research base activities; implement new strategies to improve access and participation of minority and underserved groups; and increase the professional and lay community awareness of the CCOP and benefits of clinical cancer trials. Based upon past experience, the availability of cancer control and prevention trials, multiple research bases and successful cancer control implementation models, MMCCOP investigators intend to enroll 1040 (581.6 credits/413.5 new + 168.1 follow-up) patients/participants onto NCI-approved cancer treatment and control studies during the first year, with the goal of continually exceeding the NCI requirements for both types of studies. Prior MMCCOP applications were viewed by reviewers at that time as "overly optimistic", but were exceeded. The goal for the first year of this grant is again optimistic, but realistic given the expertise of the group, available protocols, the established systems and strong support of the physicians and hospitals.